Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients' quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID) such as naproxen in addition to antibiotics may control inflammation and speed recovery. However, these studies have had too few patients to tell if there is a true benefit.
The investigators are proposing a randomized controlled trial of patients with cellulitis to compare oral naproxen (500 mg twice daily) plus oral antibiotics versus placebo plus oral antibiotics. The investigators will compare the proportion of patients who have an early clinical response (reduction in area of redness ≥20% at 72 hours), cure, treatment failure, adverse events, and hospital admission.
If naproxen proves to be superior to placebo, this simple, low-cost intervention will speed time to recovery with less pain for patients, and may potentially reduce treatment failure and time missed from activities. The results of this trial will help inform future cellulitis treatment guidelines.

Start Date01 Sep 2026

Sponsor / Collaborator

Ottawa Hospital Research Institute

[+1]

NCT07549490

/ Not yet recruitingNot ApplicableIIT

A Pilot Study for Developing a Comprehensive Signal Detection Approach for the Mechanisms of Action and Analgesic Efficacy of Two Analgesics Using Human Experimental Models of Pain (HEMP)

This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain.
The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen).
Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit.
The study includes several experimental pain tests. These include:
a heat and capsaicin skin test that causes short-term skin sensitivity,
a UVB light test that causes a temporary sunburn-like sensitivity, and
a cold pressor test, in which a hand is placed in very cold water for a short time.
Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done.
Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks.
This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....

Start Date29 Jul 2026

Sponsor / Collaborator

National Center For Complementary & Integrative Health

CTIS2026-526102-33-00

/ CompletedPhase 1

Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

Start Date11 May 2026

Sponsor / Collaborator-

100 Clinical Results associated with Naproxen

100 Translational Medicine associated with Naproxen

100 Patents (Medical) associated with Naproxen

11,704

Literatures (Medical) associated with Naproxen

01 Sep 2026·LIFE SCIENCES

Toll-like receptor 5 protects against nonsteroidal anti-inflammatory drug-induced enteropathy in mice

Article

Author: Magierowski, Marcin ; Szabó, Dóra ; Haghighi, Arezoo ; Haghighi, Samaneh ; Jakab, Anna ; Wachtl, Gerda ; Görbe, Anikó ; Gyires, Klára ; Zádori, Zoltán S ; Kökény, Gábor ; Demeter, Zsuzsanna O ; Zsidai, Anna ; Lengyel, Lili ; Ostorházi, Eszter

BACKGROUND AND AIMS:

Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause small intestinal injury, which largely depends on the presence of gut bacteria and the immune responses triggered by them. While previous studies have emphasised the role of Toll-like receptor 4 (TLR4) and TLR2 in enteropathy, the functional significance of TLR5, a receptor for bacterial flagellin, remains elusive. Thus, we aimed to assess the impact of TLR5 activation and inhibition on NSAID enteropathy in mice.

MATERIALS AND METHODS:

Enteropathy was induced using indomethacin (IND). Mucosal injury, inflammation and the mRNA levels of TLR5, TLR4 and TLR2 were assessed after 24 h. The intestinal flagellin load was measured using Western blot, while bacterial counts were assessed using qPCR. Flagellin (10 and 30 μg) and TH1020 (10 μg) were administered intraperitoneally. TLR5 levels were also determined in the ileum of naproxen-treated rats.

KEY FINDINGS:

NSAID enteropathy was associated with downregulation of TLR5, intestinal inflammation and apoptosis, mucosal histological damage, higher bacterial counts and flagellin load in the intestine, and upregulation of TLR2 and TLR4. IND-induced changes, except the fall in TLR5 expression, were reduced or completely prevented in animals that had been pretreated with flagellin. Importantly, flagellin induced similar robust protection when administered four hours after IND. In contrast to flagellin, treatment with the potent and selective TLR5 antagonist TH1020 exacerbated the intestinal inflammation caused by IND.

SIGNIFICANCE:

Our findings reveal that TLR5 activation protects against NSAID-induced enteropathy and may therefore be a new therapeutic avenue.

01 Sep 2026·WATER RESEARCH

Wastewater-impacted Skagerrak Sea microbiomes anaerobically demethylate micropollutants

Article

Author: Bonaglia, Stefano ; Fonseca, Alexis ; Krauss, Martin ; Gilevska, Tetyana ; Rotaru, Amelia-Elena ; Anestis, Konstantinos ; Inostroza, Pedro A ; Kümmel, Steffen

Methylated micropollutants such as naproxen and caffeine persist in wastewater effluents and accumulate in coastal sediments, including Hakefjorden, Skagerrak Sea, yet their anaerobic fate and role in methane emissions remain unresolved. In particular, it is unclear whether pollutant-derived methyl groups are routed mainly to CO₂ or can be transformed into CH₄ in sulfate-rich coastal sediments. Our primary objective was to resolve this routing by tracing the fate and microbiome responses to ¹³C-labeled naproxen and caffeine in sediment microcosms. We show that naproxen underwent rapid O-demethylation to desmethylnaproxen, with 90% ± 15.5% removed within 25 days, producing primarily ¹³CO₂ and some ¹³CH₄. Naproxen enriched methylotrophic and hydrogenotrophic Methanomicrobia, alongside Lokiarchaeia, Bathyarchaeia, and bacterial taxa like Eubacterium (Alkalibaculum A sporogenes) and Syntrophomonadaceae. Metagenomics revealed O-demethylation genes in enriched bacterial MAGs affiliated with uncultured Thermoanaerobaculia, indicating a bacterial demethylation potential. In contrast, caffeine was largely recalcitrant to degradation (∼85% ± 5% remaining), yet its ¹³C-labeled N-methyl groups fueled trace ¹³CH₄ production. These results show that methylated micropollutants can activate both bacterial and archaeal demethylation pathways in coastal sediment microbiomes.

01 Aug 2026·WATER RESEARCH

Impact of micropollutants and the process configuration on the performance of moving bed membrane biofilm reactor (MBMBR)

Article

Author: Bal, Yamac ; Pak, Burak Aslancan ; Sahinkaya, Erkan ; Hatib, Baraa Ahmed ; Bayrakdar, Alper

This study investigates the removal performance of selected micropollutants (ibuprofen, diclofenac, naproxen, carbamazepine, and triclosan) from domestic wastewater using a moving bed membrane biofilm reactor (MBMBR) process, consisting of two moving bed biofilm reactors (MBBRs) in series followed by a membrane bioreactor (MBR). While the integration of MBBR and MBR processes leverages the advantages of both technologies, systematic studies on determining the optimal configuration, particularly in the presence of micropollutants, remain quite limited in the literature. Within the scope of the research, the effects of sludge recirculation (hybrid growth) from the MBR to different MBBR units on treatment performance were evaluated over 140 days with three different periods. The results showed that the COD removal efficiency, which was initially 98% (permeate COD <10 mg/L), gradually decreased following the introduction of micropollutants. The toxicity of micropollutants led to the accumulation of soluble microbial products (SMPs) and extracellular polymeric substances (EPSs), which increased the average supernatant COD up to 370 mg/L in the MBR unit. The membrane rejected most of the SMPs and EPSs, which improved the permeate quality (with permeate COD averaging <50 mg/L in all configurations) but increased the fouling potential. Nitrification almost entirely ceased (with permeate NH₄⁺-N averaging 40 mg/L) during the second period (biofilm-only growth) as the system suffered from both micropollutant toxicity and the lack of microbial seeding by sludge recirculation. Regarding micropollutant removal, high efficiencies of over 75% were achieved for ibuprofen and triclosan, while removal efficiencies for recalcitrant compounds such as carbamazepine, diclofenac, and naproxen generally remained below 30%. This study highlights the impact of micropollutants on ammonia oxidizing bacteria (AOB), which may have a critical role in micropollutant removal, and demonstrates the advantages of the hybrid growth mode in maintaining process stability.

News (Medical) associated with Naproxen

24 Jul 2026

·www.prnewswire.com

FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)

TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief in a single dose. FDA-approved first and only OTC fixed ‑ dose combination of acetaminophen and naproxen sodium, expanding non-opioid options for persistent pain. Addresses a critical gap in persistent pain relief – 75% of persistent pain sufferers report dissatisfaction with current options (Kenvue Pain Consumer Survey, March 2026, n=6,240). Simplifies pain management with a single, clinically proven fixed-dose combination, eliminating the need to time or coordinate multiple over-the-counter pain relievers. Backed by eight clinical studies demonstrating superior pain relief versus acetaminophen alone and naproxen sodium alone (Aleve1 220 mg). Builds on more than 70 years of TYLENOL® leadership in pain relief innovation, advancing a more streamlined, multimodal approach for patients and healthcare providers. SUMMIT, N.J., July 24, 2026 /PRNewswire/ -- TYLENOL®, the #1 doctor‑recommended pain relief brand, today announced that the U.S. Food and Drug Administration (FDA) has approved TYLENOL® with Naproxen — the first and only over‑the‑counter (OTC) fixed‑dose combination of acetaminophen and naproxen sodium — redefining what's possible in non-prescription pain management. TYLENOL® with Naproxen combines the fast-acting relief of 650 mg of acetaminophen with the long-lasting analgesic power of 220 mg naproxen sodium (a non-steroidal anti-inflammatory drug) in one dose, which begins working in under 30 minutes and provides relief for 12 hours. According to the Kenvue Pain Consumer Survey (March 2026, n=6,240), an estimated 75% of persistent pain sufferers report dissatisfaction with their current relief options, and the U.S. Department of Labor reports that up to 1 in 4 patients prescribed opioids are at risk of addiction. TYLENOL® with Naproxen addresses this gap by combining two well-established non-opioid pain relievers into a single, clinically proven OTC therapeutic solution that requires no prescription and carries no opioid risk. For many patients, managing persistent pain has meant navigating a complex, multi-step approach involving multiple medications, staggered dosing schedules, or prescription options. TYLENOL® with Naproxen helps simplify pain management with a multimodal OTC option designed to support both adherence and relief. The FDA has granted TYLENOL® a three-year period of exclusivity for this new OTC formulation, underscoring the significance of this innovation in serving those suffering from pain. Delivering Innovation Backed by Decades of Pain Relief Leadership Building on more than 70 years of leadership in acetaminophen science, safety and stewardship, TYLENOL® with Naproxen expands the brand's long history of category-defining innovation. Milestones include introducing the first children's liquid acetaminophen product, and for adults, helping to establish higher-dose OTC pain relief as a new category standard with the launch of 500 mg Extra Strength TYLENOL®. "This milestone reflects the long-standing leadership of TYLENOL® in translating rigorous clinical science into accessible, over‑the‑counter solutions," said Dr. Rajesh Mishra, MD, PhD; Chief Medical Officer, Kenvue. "Persistent pain often leaves people trapped in a cycle of trial and error, navigating between choosing short-term relief or more complex treatment options. TYLENOL® with Naproxen simplifies that choice, offering fast onset, 12-hour duration, and the safety profile of two well-established non-opioid ingredients in one fixed-dose." Robust Clinical Evidence Supporting Efficacy and Use Across eight clinical studies, TYLENOL® with Naproxen demonstrated: Superior pain relief versus acetaminophen alone and naproxen sodium (Aleve 220mg) alone. Onset of relief in under 30 minutes. Duration of relief for 12 hours in a single dose. Clinical data demonstrating the efficacy and use of TYLENOL® with Naproxen across multiple pain models will be presented at upcoming medical congresses, including PAINWeek 2026. "The clinical program behind TYLENOL® with Naproxen was designed to answer a practical question: could we deliver fast onset and sustained pain relief in a single, opioid-free OTC option, without asking patients to combine multiple products on their own? Across the eight clinical studies supporting the FDA approval, the 650 mg acetaminophen and 220 mg naproxen sodium fixed-dose combination consistently outperformed either ingredient alone. What makes this meaningful for clinicians is not just the efficacy; it's the rigor of the development program and the fact that patients can now access a clinically proven fixed-dose combination over-the-counter," said Todd Bertoch, MD, Chief Medical Officer, Pain Research at CenExel Clinical Research, Inc., and a principal investigator on the TYLENOL® with Naproxen clinical program. TYLENOL® with Naproxen will be coming soon to major U.S. retailers nationwide. To learn more, visit or follow TYLENOL® on Instagram and TikTok. About TYLENOL® with Naproxen What is TYLENOL® with Naproxen? TYLENOL® with Naproxen is the first and only FDA-approved over-the-counter pain reliever that combines 650 mg of acetaminophen and 220 mg of naproxen sodium in a fixed-dose. It is indicated for the temporary relief of pain and is available without a prescription. How is it different from regular TYLENOL® or Aleve? Single-ingredient TYLENOL® contains acetaminophen only. Aleve contains naproxen sodium only. TYLENOL® with Naproxen combines the fast-acting relief of acetaminophen with the long-lasting power of a non-steroidal anti-inflammatory drug, naproxen sodium – starting to work in under 30 minutes and delivering effective pain relief for 12 hours. How does TYLENOL® with Naproxen work? Acetaminophen is believed to work quickly to reduce pain signals. Naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID), provides longer-lasting relief by targeting pain caused by inflammation. Combining them in a single dose delivers both fast onset and extended duration of pain relief. Is TYLENOL® with Naproxen an opioid? No. TYLENOL® with Naproxen is opioid-free. It is intended to expand non-opioid pain management options for patients and healthcare providers. When and where will TYLENOL® with Naproxen be available? TYLENOL® with Naproxen will be coming soon to major U.S. retailers nationwide. The FDA has granted Kenvue a three-year period of exclusivity for this new OTC formulation. Who should not take TYLENOL® with Naproxen? Consumers should always read and follow the Drug Facts label and talk with a healthcare professional if they have questions about whether TYLENOL® with Naproxen is right for them. About TYLENOL® TYLENOL® – the #1 doctor-recommended brand of pain and fever relief – offers a growing portfolio of products designed to help people manage their health. From trusted OTC medicines to innovative topicals, TYLENOL® is committed to providing Care Without Limits™ by addressing a wide range of needs across ages and through every stage of life. TYLENOL® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the development of TYLENOL® with Naproxen. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. and its affiliates. A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent Quarterly Reports on Form 10-Q and other filings, available at or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise. 1 Aleve is a trademark of Bayer Healthcare LLC Media Contact: Sam Higgins ([email protected]) SOURCE Kenvue Inc. 21% more press release views with Request a Demo

Drug Approval

24 Jul 2026

·www.pharmaindustrial-india.com

US FDA Approves TYLENOL with Naproxen for OTC Use

TYLENOL recently announced that the US Food and Drug Administration (FDA) has approved TYLENOL with Naproxen—the first and only Over?the?Counter (OTC) fixed?dose combination of acetaminophen and naproxen sodium—redefining what's possible in non-prescription pain management. TYLENOL with Naproxen combines the fast-acting relief of 650 mg of acetaminophen with the long-lasting analgesic power of 220 mg naproxen sodium (a non-steroidal anti-inflammatory drug) in one dose, which begins working in under 30 minutes and provides relief for 12 hours. According to the Kenvue Pain Consumer Survey (March 2026, n=6,240), an estimated 75 percent of persistent pain sufferers report dissatisfaction with their current relief options, and the US Department of Labor reports that up to 1 in 4 patients prescribed opioids are at risk of addiction. TYLENOL with Naproxen addresses this gap by combining 2 well-established non-opioid pain relievers into a single, clinically proven OTC therapeutic solution that requires no prescription and carries no opioid risk. For many patients, managing persistent pain has meant navigating a complex, multi-step approach involving multiple medications, staggered dosing schedules, or prescription options. It helps simplify pain management with a multimodal OTC option designed to support both adherence and relief. The FDA has granted TYLENOL a 3-year period of exclusivity for this new OTC formulation, underscoring the significance of this innovation in serving those suffering from pain.

Drug Approval

16 Jul 2026

·www.globenewswire.com

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain ManagementSOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Research Society 2026 Annual Symposium recently held in Dijon, France. In the nonclinical OA study, oral administration of ART26.12 significantly reduced osteoarthritis-associated pain behaviors following both acute and chronic dosing over a 4-week period, demonstrating efficacy comparable to naproxen, a widely prescribed nonsteroidal anti-inflammatory drug (NSAID) used to treat OA. ART26.12 produced distinct changes in endocannabinoids and other related bioactive lipids and proteins compared to naproxen, supporting a novel mechanism of action for ART26.12. Importantly, animals treated with ART26.12 exhibited significantly less stomach tissue damage, including non-glandular hyperkeratosis, compared to those receiving naproxen. Non-glandular hyperkeratosis is considered an early indicator of erosions and gastric ulcers, a well-recognized and potentially serious complication associated with chronic NSAID use. These findings suggest ART26.12 may offer effective pain relief with the potential for an improved gastrointestinal safety profile. Professor Kaczocha commented, “Osteoarthritis affects more than 30 million Americans and a novel drug such as ART26.12 could provide a new option for patients to achieve pain relief with potentially fewer side-effects compared to existing NSAIDs.” Long-term treatment options for OA remain constrained by the safety concerns associated with chronic NSAID use, including gastrointestinal complications that contribute to significant morbidity and healthcare costs each year. These limitations highlight the need for differentiated therapies, and new preclinical findings further validate FABP5 as a promising target for the treatment of chronic pain while reinforcing the broad therapeutic potential of ART26.12. The data demonstrated that inhibition of FABP5 significantly alleviated osteoarthritis-associated pain, expanding the potential clinical utility of ART26.12 beyond neuropathic pain into one of the largest and most prevalent chronic pain markets. Importantly, ART26.12 delivered pain relief comparable to naproxen while exhibiting significantly less gastric tissue damage in preclinical studies, supporting the potential for an improved gastrointestinal safety profile. Collectively, these findings further support the continued development of ART26.12 as a differentiated, non-opioid pain therapy with the potential to address multiple chronic pain indications through its novel mechanism of action. “Chronic pain remains one of the largest areas of unmet medical need, with patients continuing to rely on therapies that often provide inadequate relief or carry significant safety concerns,” said Andy Yates, PhD, Chief Scientific Officer of Artelo. “The growing body of evidence supporting ART26.12 across multiple pain models, along with a low toxicological non-clinical risk and a well-tolerated clinical profile, reinforces our belief that selective FABP5 inhibition may represent a differentiated approach to treating chronic pain and inflammatory disorders. These findings continue to strengthen the scientific rationale for ART26.12 as a potential first-in-class analgesic candidate with utility across multiple disease settings.” Preparations are underway for conducting a clinical multiple ascending repeat dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. Artelo anticipates enrollment will commence during the fourth quarter of this year. About ART26.12ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is under development as a novel, peripherally acting, non-opioid, non-steroidal analgesic, initially for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable safety profile with no serious adverse events, as well as predictable, linear pharmacokinetics and dosing flexibility in both fed and fasted states. Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. In addition to ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo BiosciencesArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial practices to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Clinical Result

100 Deals associated with Naproxen

External Link

KEGG	Wiki	ATC	Drug Bank
D00118	Naproxen	G02CC02 M01AE02 M02AA12	DB00788

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1983
Gout	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1982
Analgesia	Japan	Nipro ES Pharma KK	24 Jan 1978
Inflammation	Japan	Nipro ES Pharma KK	24 Jan 1978
Ankylosing Spondylitis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Juvenile Idiopathic Arthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Osteoarthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976
Rheumatoid Arthritis	United States	Atnahs Pharma US Ltd.	11 Mar 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	-	Targeted Medical Pharma, Inc.	01 Feb 2009
Toothache	Phase 2	United States	Iroko Pharmaceuticals LLC	01 Oct 2010
Peptic Ulcer	Phase 1	United Kingdom	Oxford Pharmascience Ltd.	01 May 2015
Rheumatic Diseases	Phase 1	United Kingdom	Oxford Pharmascience Ltd.	01 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02502006 (Pubmed \| Hypertension)	Phase 2	-	16	Celecoxib 200 mg/d	rikdpgjmvb(rwxkazzxog) = lwsdqdktpz ccspgrhmkh (fgghztsxnq )	Positive	01 Feb 2026
				Naproxen 500 mg/d	axpbkmbfga(xladefluof) = cznvwraqxq ajatrobwrc (qurngubyvq ) View more
NCT04115098 (Pubmed \| Rheumatology (Oxford))	Phase 2	Axial Spondyloarthritis	30	celecoxib	uzqvklpxit(cdvlvondai) = xwxittovha bnhcbjbsnv (nusgzklekx )	Positive	01 Dec 2025
				naproxen	uzqvklpxit(cdvlvondai) = iycmwrqtzn bnhcbjbsnv (nusgzklekx )
ACR2025	Not Applicable	Axial Spondyloarthritis	30	Celecoxib	rwyfnvnvia(vgukuqygxi) = Adverse events were infrequent and mild across all NSAIDs, with only one serious adverse event (diarrhea) reported. qgcpkyxrtl (ihmjpzpvxm ) View more	Positive	24 Oct 2025
				Meloxicam
NCT03493945 (QuEST1, CTgov)	Phase 1/2	Locally Advanced Malignant Solid Neoplasm \| Advanced Malignant Solid Neoplasm	59	castration+M7824+BN-Brachyury (Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A)	yondknghib = ugcbqssmhc kcmbmygvti (oftnqtbkop, liakahfdsu - fueedbxrtu) View more	-	08 Jun 2025
				N-803+N803+M7824+BN-Brachyury (All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion)	yondknghib = dgzkityfvj kcmbmygvti (oftnqtbkop, knunfkfpbh - jcbxjkbgbt) View more
NCT03771612 (CTgov)	Early Phase 1	Inflammation	144	Naproxen (Naproxen)	pellbdgsda(qryvypuddp) = uzzbkgftjv dqtwbjawpl (cfhtzddzfx, 10) View more	-	25 Feb 2025
				Placebos (Placebo)	pellbdgsda(qryvypuddp) = zbfqyznewv dqtwbjawpl (cfhtzddzfx, 10.5) View more
NCT05026320 (CTgov)	Phase 2	Contusions \| Soft Tissue Injuries	76	Placebo gel	uopkaiwmib(yadczoojrh) = lbhkyqojby mrymeyjene (kvsnzdbbah, bbemcexocl - ynzhzipkzb) View more	-	22 Jan 2025
NCT02451748 (CTgov)	Phase 4	Rheumatoid Arthritis	32	Lab Work (DMARD's Responder and Non-Responder)	cggqtoijcx(aylwzrskeg) = xpbbdeiphn unpubvtdkx (twgqjytkbn, xcapfnszhn - lruxhtzbxe) View more	-	10 Jul 2024
				Naproxen+Medrol+Hydroxychloroquine+humira+prednisone+Lab Work+Triamcinolone+Methotrexate+Sulfasalazine+CDP870+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol))	fqwhzzcahl(ynutukpmph) = yqszaiaapf zrlbwrnwcm (tpsbjzixtk, 0.132) View more
NCT03347929 (Pubmed \| Pain) Manual	Phase 4	Sciatica	123	Naproxen 500 mg	rgmwqisloo(hevpzsrkzf) = gqselathho tteovvkjsm (yfrbmbwbrs ) View more	Negative	04 Jun 2024
				Placebo	-
NCT04694300 (CTgov)	Phase 4	Mouth and Tooth Diseases \| Acute Pain	30	Tramadol+Naproxen (Naproxen Sodium)	dorvzharrp(tzbdnbxofn) = wlizvsaeof rqelubrdnu (gqdopstdvy, ayxllixsen - vvwhtglspk) View more	-	16 May 2024
				Tramadol+Acetaminophen (Acetaminophen)	dorvzharrp(tzbdnbxofn) = yfxlsymmfx rqelubrdnu (gqdopstdvy, hlcgqjgqoq - pvgnqiukaf) View more
NCT02502006 (CTgov)	Phase 1	-	16	Celecoxib (Celecoxib)	qmsknnuxeg(edelsmwjtn) = zcsggseeuv ohbmvkpokz (tsnparshir, 1357) View more	-	13 Dec 2023
				Naproxen (Naproxen)	qmsknnuxeg(edelsmwjtn) = hccltwsimo ohbmvkpokz (tsnparshir, 66.8) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis